FDA Approves Cablivi, First Therapy to Treat aTTP

By Marie Rosenthal

The FDA approved caplacizumab-yhdp (Cablivi, Sanofi) injection, the first therapy specifically indicated—in combination with plasma exchange and immunosuppressive therapy—for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), a rare and life-threatening blood clotting disorder.

Patients with aTTP develop extensive blood clots in the small blood vessels throughout the body, which can cut off oxygen and blood supply to the major